Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q1 2022 Earnings Presentation
23 slides from Autolus Therapeutics's earnings presentation, May 5, 2022
Slide 1: First Quarter Financial Results and Operational Progress
First Quarter Financial Results and Operational Progress May 5 2022
Slide 2: Disclaimer
Developing Next Generation Programmed T Cell Therapies Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical
Slide 3: Agenda
Developing Next Generation Programmed T Cell Therapies Autolus.com 3 Agenda • Welcome and Introduction: Olivia Manser, Director, Investor Relations • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Dr. Lucinda Crabtree, CFO • Upcoming Milestones and Conclusion: Dr. Christian Iti
Slide 4: Autolus Overview
Developing Next Generation Programmed T Cell Therapies Autolus.com 4 Autolus Overview Building a fully integrated CAR T company Best-in-class Scalable Pipeline Collaboration lead asset manufacturing • Lead product obe-cel • Pipeline built on • In house cell • Collaboration with potentially best-in-c
Slide 5: Program updates – first quarter 2022
Developing Next Generation Programmed T Cell Therapies Autolus.com 5 Program updates – first quarter 2022 Strong progress, with multiple clinical readouts in 2022 • obe-cel in relapsed / refractory (r/r) adult ALL – continuing to enroll patients into the FELIX study – FELIX study passed futility ana
Slide 6: Key operational updates – first quarter 2022
Developing Next Generation Programmed T Cell Therapies Autolus.com 6 Key operational updates – first quarter 2022 Continued progress on building a leading ALL company • Good progress on the build phase of the Company’s new manufacturing facility in Stevenage, UK • Dr. Lucinda Crabtree replaced Andre
Slide 7: obe-cel
LEAD CLINICAL PROGRAM obe-cel A standalone, potentially best-in-class CD19 CAR T cell therapy
Slide 8: obe-cel has a unique mechanism of action
Developing Next Generation Programmed T Cell Therapies Autolus.com 8 obe-cel has a unique mechanism of action • Fast off-rate obe-cel has lower CD19 affinity and shorter CAT binder with On-Rate: Ka [M-1S-1] ] 1 - Other CD19 Binders Obe-cel Binder half-life of interaction compared to binders S lower
Slide 9: obe-cel for adult ALL: high unmet need
Developing Next Generation Programmed T Cell Therapies Autolus.com 9 obe-cel for adult Acute Lymphoblastic Leukemia (ALL): high unmet need Successful therapy requires high level of activity and sustained persistence paired with good tolerability • Combination chemotherapy enables 90% of adult ALL pa
Slide 10: obe-cel is a potentially transformational therapy for adult ALL
Developing Next Generation Programmed T Cell Therapies Autolus.com 10 obe-cel is a potentially transformational therapy for adult ALL Unique CAR T design built on a fast off-rate from CD19 target antigendrives differentiated product profile obe-cel • Initial FELIX Phase 1b data presented at ASH, Dec
Slide 11: Next steps: obe-cel initial data (FELIX) expected in H2 2022
Developing Next Generation Programmed T Cell Therapies Autolus.com 11 Next steps: obe-cel initial data (FELIX) expected in H2 2022 obe-cel is the first Autolus program to move into a potential pivotal program: futility analysis passed during the quarter Primary endpoint: H2 2022 overall complete Ini
Slide 12: Building obe-cel into a franchise
Building obe-cel into a franchise Deep value program with broad applicability
Slide 13: Capitalising on the obe-cel profile in additional indications
Developing Next Generation Programmed T Cell Therapies Autolus.com 13 Capitalising on the obe-cel profile in additional indications Unique profile allows applicability in a broad range of indications Clinical data supports differentiated product profile • High degree of activity and persistence -> d
Slide 14: AUTO1/22: Pediatric Acute Lymphoblastic Leukemia
Developing Next Generation Programmed T Cell Therapies Autolus.com 14 AUTO1/22: Pediatric Acute Lymphoblastic Leukemia CD19 negative antigen escape is a common cause of treatment failure CARPALL Study • obe-cel (AUTO1) in relapsed / refractory pediatric ALL is highly active and has a favourable safe
Slide 15: Pipeline
Pipeline A broad portfolio of next generation modular T cell therapies
Slide 16: A broad toolkit which is core to our strategy of modular innovation
Developing Next Generation Programmed T Cell Therapies Autolus.com 16 A broad toolkit which is core to our strategy of modular innovation Advanced T cell programming Viral Vector Advanced Targeting Modules Pharmacological Control Modules Activity Enhancement Modules Allogeneic Programming Modules Vi
Slide 17: Pipeline beyond obe-cel
Developing Next Generation Programmed T Cell Therapies Autolus.com 17 Pipeline beyond obe-cel Designed to address limitations of current T cell therapies PRODUCT INDICATION TARGET STUDY PRE PHASE 1 PHASE 2/ BLA CLINICAL PIVOTAL AUTO4 TRBC1+ Peripheral TCL TRBC1 LibrA T1 AUTO5 TRBC2+ Peripheral TCL T
Slide 18: AUTO4: T Cell Lymphoma
Developing Next Generation Programmed T Cell Therapies Autolus.com 18 AUTO4: T Cell Lymphoma No standard of care after first relapse and no T cell therapy approved • T cell lymphoma is an aggressive disease with a very Three key elements to address T cell lymphomas: poor prognosis for patients AUTO4
Slide 19: Financial Results
Financial Results
Slide 20: Financial summary
Developing Next Generation Programmed T Cell Therapies Autolus.com 20 Financial summary Cash runway into 2024, assuming Blackstone milestones received USD m Q1 2022 Q1 2021 Variance Grant Income 0.2 0.3 (0.1) License Income - - - R&D (34.0) (30.7) (3.3) G&A (8.0) (8.7) 0.7 Loss on disposal of leaseh
Slide 21: Summary
Summary Multiple catalysts in H2 2022
Slide 22: Autolus poised for potential value inflection
Developing Next Generation Programmed T Cell Therapies Autolus.com 22 Autolus poised for potential value inflection obe-cel pivotal data in adult ALL in 2022 • obe-cel – FELIX Phase 2 study in adult ALL ongoing; initial data expected in H2 2022 and full data in H1 2023 – Evaluation in r/r B-NHL and
Slide 23: Thank you
Thank you autolus.com